新型心血管设备技术对医疗保健成本的影响。
The impact of new cardiovascular device technology on health care costs.
作者信息
Groeneveld Peter W, Polsky Daniel, Yang Feifei, Yang Lin, Epstein Andrew J
出版信息
Arch Intern Med. 2011 Jul 25;171(14):1289-91. doi: 10.1001/archinternmed.2011.141. Epub 2011 Apr 25.
Abstract
Drug-eluting coronary stents (DES) are widely used and entail sizeable Medicare hospital expenditures. However, the overall cost impact of DES has not been well quantified. Clear understanding of how new technologies like DES affect healthcare expenditures can provide insight into national trends in healthcare cost growth, of which new technology is presumably the leading driver. New technology may not only increase costs by being more expensive than previous treatments, but also by changing the patterns of care for chronic disease. Accordingly, we sought to assess the overall impact of DES on Medicare expenditures in a nationally-representative cohort of Medicare beneficiaries with coronary artery disease (CAD).
摘要
药物洗脱冠状动脉支架（DES）被广泛使用，并且导致医疗保险医院支出大幅增加。然而，DES对总体成本的影响尚未得到充分量化。清楚了解像DES这样的新技术如何影响医疗保健支出，可以洞察医疗保健成本增长的全国趋势，而新技术大概是这一趋势的主要驱动因素。新技术不仅可能因其比先前治疗更昂贵而增加成本，还可能通过改变慢性病护理模式来增加成本。因此，我们试图在全国代表性的患有冠状动脉疾病（CAD）的医疗保险受益人群队列中评估DES对医疗保险支出的总体影响。
相似文献
1
The impact of new cardiovascular device technology on health care costs.
Arch Intern Med. 2011 Jul 25;171(14):1289-91. doi: 10.1001/archinternmed.2011.141. Epub 2011 Apr 25.
2
Cardiovascular device technology and health care cost.
Arch Intern Med. 2011 Oct 10;171(18):1689; author's reply 1689. doi: 10.1001/archinternmed.2011.464.
3
Drug-eluting stents: more dollars than sense?
JACC Cardiovasc Interv. 2009 Dec;2(12):1188-9. doi: 10.1016/j.jcin.2009.11.001.
4
Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions).
JACC Cardiovasc Interv. 2009 Dec;2(12):1178-87. doi: 10.1016/j.jcin.2009.10.011.
5
Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
JACC Cardiovasc Interv. 2009 Dec;2(12):1199-207. doi: 10.1016/j.jcin.2009.10.009.
6
[Can PCI with drug-eluting stents replace coronary artery bypass surgery? A comparative economic analysis regarding both therapeutic options based on clinical 12-month data reflecting the German social health care insurance system].
Herz. 2005 Jun;30(4):332-8. doi: 10.1007/s00059-005-2694-5.
7
Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial.
JACC Cardiovasc Interv. 2017 Apr 24;10(8):774-782. doi: 10.1016/j.jcin.2017.01.022.
8
The costs of drug-eluting coronary stents among Medicare beneficiaries.
Am Heart J. 2008 Jun;155(6):1097-105. doi: 10.1016/j.ahj.2008.01.012. Epub 2008 Mar 19.
9
Health Economic Evaluation of an Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Compared to a Thin, Durable-Polymer Everolimus-Eluting Stent.
Cardiovasc Revasc Med. 2019 Sep;20(9):752-757. doi: 10.1016/j.carrev.2018.11.006. Epub 2018 Nov 20.
10
Second-generation drug-eluting stents and the continuous need for rapidly available real-world data.
JACC Cardiovasc Interv. 2009 Dec;2(12):1236-9. doi: 10.1016/j.jcin.2009.10.010.
引用本文的文献
1
Preoperative management of antiplatelet drugs for a coronary artery stent: how can we hit a moving target?
BMC Anesthesiol. 2014 Aug 23;14:73. doi: 10.1186/1471-2253-14-73. eCollection 2014.
2
Predicting target vessel revascularization in older patients undergoing percutaneous coronary intervention in the drug-eluting stent era.
Am Heart J. 2014 Apr;167(4):576-584.e2. doi: 10.1016/j.ahj.2013.12.017. Epub 2014 Jan 4.
3
Another view of personalized medicine: optimizing stent selection on the basis of predicted benefit in percutaneous coronary intervention.
Trends Cardiovasc Med. 2012 Jan;22(1):23-8. doi: 10.1016/j.tcm.2012.06.006. Epub 2012 Jul 28.
4
Variations in the use of an innovative technology by payer: the case of drug-eluting stents.
Med Care. 2012 Jan;50(1):1-9. doi: 10.1097/MLR.0b013e31822d5de9.
本文引用的文献
1
2006 National Hospital Discharge Survey.
Natl Health Stat Report. 2008 Jul 30(5):1-20.
2
Optimal medical therapy with or without PCI for stable coronary disease.
N Engl J Med. 2007 Apr 12;356(15):1503-16. doi: 10.1056/NEJMoa070829. Epub 2007 Mar 26.
3
Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis.
Circulation. 2005 Jun 7;111(22):2906-12. doi: 10.1161/CIRCULATIONAHA.104.521864. Epub 2005 May 31.
4
Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial.
Circulation. 2004 Aug 3;110(5):508-14. doi: 10.1161/01.CIR.0000136821.99814.43. Epub 2004 Jul 19.
5
Racial disparity in cardiac procedures and mortality among long-term survivors of cardiac arrest.
Circulation. 2003 Jul 22;108(3):286-91. doi: 10.1161/01.CIR.0000079164.95019.5A. Epub 2003 Jun 30.
6
Medical care costs: how much welfare loss?
J Econ Perspect. 1992 Summer;6(3):3-21. doi: 10.1257/jep.6.3.3.
7
Diffusion of laparoscopic cholecystectomy among general surgeons in the United States.
Med Care. 1995 Mar;33(3):256-71. doi: 10.1097/00005650-199503000-00005.
Zotero 插件